Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cameron J Turtle

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Blood|February 16, 2013
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivoSuzanne M McGoldrick, Marie E Bleakley, Abraham Guerrero, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 4, 2017
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell ProductsKenneth Cornetta, Lisa Duffy, Cameron J Turtle, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 14, 2018
Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire DiversityPaul Lindau, Rithun Mukherjee, Miriam V Gutschow, et al.
Blood|August 27, 2009
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cellsHarlan S Robins, Paulo V Campregher, Santosh K Srivastava, et al.
Blood|July 28, 2011
Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cellsCameron J Turtle, Jeff Delrow, Rochelle C Joslyn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapyKristen J Radford, Cameron J Turtle, Andrew J Kassianos, et al.
Blood|October 18, 2017
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapyJoshua A Hill, Daniel Li, Kevin A Hay, et al.
Blood Advances|July 22, 2020
Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemiaRyan D Cassaday, Kelsey-Leigh A Garcia, Jonathan R Fromm, et al.
Cytotherapy|February 27, 2009
Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivityKenneth P Micklethwaite, Frances M Garvin, Melina R Kariotis, et al.
Blood Advances|October 19, 2021
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapyKrishna R Juluri, Qian Vicky Wu, Jenna Voutsinas, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Blood|February 16, 2013
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivoSuzanne M McGoldrick, Marie E Bleakley, Abraham Guerrero, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 4, 2017
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell ProductsKenneth Cornetta, Lisa Duffy, Cameron J Turtle, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 14, 2018
Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire DiversityPaul Lindau, Rithun Mukherjee, Miriam V Gutschow, et al.
Blood|August 27, 2009
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cellsHarlan S Robins, Paulo V Campregher, Santosh K Srivastava, et al.
Blood|July 28, 2011
Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cellsCameron J Turtle, Jeff Delrow, Rochelle C Joslyn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapyKristen J Radford, Cameron J Turtle, Andrew J Kassianos, et al.
Blood|October 18, 2017
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapyJoshua A Hill, Daniel Li, Kevin A Hay, et al.
Blood Advances|July 22, 2020
Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemiaRyan D Cassaday, Kelsey-Leigh A Garcia, Jonathan R Fromm, et al.
Cytotherapy|February 27, 2009
Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivityKenneth P Micklethwaite, Frances M Garvin, Melina R Kariotis, et al.
Blood Advances|October 19, 2021
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapyKrishna R Juluri, Qian Vicky Wu, Jenna Voutsinas, et al.
Pageof 13